Patiromer for the treatment of hyperkalemia

References

• Rosano GMC, Tamargo J, Kjeldsen KP, et al. Expert consensus document on the management of hyperkalemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the working group on cardiovascular pharmacotherapy of the European society of cardiology. Eur Heart J – Card Pharm. 2018;4:180–188.
   Web of Science ®Google Scholar
• Hoenig MP, Zeidel ML. Homeostasis, the milieu intérieur, and the wisdom of the nephron. Clin J Am Soc Nephrol. 2014;9:1272–1281.
   PubMed Web of Science ®Google Scholar
• Epstein M. Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena. Kidney Int Suppl. 2016;1:20–28.
   Web of Science ®Google Scholar
• Epstein M, Pitt B. Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer. Expert Opin Pharmacother. 2016;17:1435–1448.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America. J Card Fail. 2017;23:628–651.
   PubMed Web of Science ®Google Scholar
• Krogager ML, Torp-Pedersen C, Mortensen RN, et al. Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data. Eur Heart J. 2017;38:104–112.
   PubMed Web of Science ®Google Scholar
• Fitch K, Woolley JM, Engel T, et al. The clinical and economic burden of hyperkalemia on medicare and commercial payers. Am Health Drug Benefits. 2017;10:202–210.
   PubMed Web of Science ®Google Scholar
• Mendes A. The KDIGO roadmap to improving care in chronic kidney disease. Journal of Kidney Care. 2016;1:205.
   Google Scholar
• Clegg DJ, Cody M, Palmer BF. Challenges in treating cardiovascular disease: restricting sodium and managing hyperkalemia. Mayo Clin Proc. 2017;92:1248–1260.
   PubMed Web of Science ®Google Scholar
• Ouwerkerk W, Voors AA, Cleland JG, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J. 2017;38:1883–1890.
   PubMed Web of Science ®Google Scholar
• Georgianos PI, Agarwal R. Revisiting RAAS blockade in CKD with newer potassium-binding drugs. Kidney Int. 2018 Feb;93(2):325–334.
   PubMed Web of Science ®Google Scholar
• Pitt B, Bakris GL. New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future. Hypertension. 2015;66:731–738.
   PubMed Web of Science ®Google Scholar
• Palmer BF. A physiologic-based approach to the evaluation of a patient with hyperkalemia. Am J Kidney Diseases. 2010;56:387–393.
   PubMed Web of Science ®Google Scholar
• Kessler C, Ng J, Valdez K, et al. The use of sodium polystyrene sulfonate in the inpatient management of hyperkalemia. J Hosp Med. 2011;6:136–140.
   PubMed Web of Science ®Google Scholar
• Lepage L, Dufour AC, Doiron J, et al. Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD. Clin J Am Soc Nephrol. 2015;10:2136–2142.
   PubMed Web of Science ®Google Scholar
• Flinn RB, Merrill JP, Welzant WR. Treatment of the oliguric patient with a new sodium-exchange resin and sorbitol; a preliminary report. N Engl J Med. 1961;264:111–115.
   PubMed Web of Science ®Google Scholar
• McCullough PA, Beaver TM, Bennett-Guerrero E, et al. Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management. Rev Cardiovasc Med. 2014;15:11–23.
   PubMed Web of Science ®Google Scholar
• McGowan CE, Saha S, Chu G, et al. Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol. South Med J. 2009;102:493–497.
   PubMed Web of Science ®Google Scholar
• Kayexalate. Sodium polystyrene sulfonate, USP. [cited 2020 May 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/011287s023lbl.pdf
   Google Scholar
• Laureati P, Xu Y, Trevisan, et al. Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study. Nephrol Dial Transplant. 2019 Aug 4 Epub ahead of print. DOI: 10.1093/ndt/gfz150.
   PubMed Web of Science ®Google Scholar
• Stavros F, Leon A, Yang A, et al. In vitro ion exchange capacity and selectivity of zs-9, a novel, selective cation trap for the treatment of hyperkalemia. Am J Kidney Diseases. 2014;63:B115.
   Web of Science ®Google Scholar
• Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA. 2014;312:2223–2233.
   PubMed Web of Science ®Google Scholar
• Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372:211–221.
   PubMed Web of Science ®Google Scholar
• Li L, Harrison SD, Buysse J, et al. Mechanism of action and pharmacology of patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia. J Cardiovasc Pharmacol Ther. 2016;21:456–465.
   PubMed Web of Science ®Google Scholar
• Fordtran JS, Locklear TW. Ionic constituents and osmolality of gastric and small-intestinal fluids after eating. Am J Digestive Dis. 1966;11:503–521.
   PubMedGoogle Scholar
• Veltassa Package Insert. [cited 2020 May 19]. https://www.veltassa.com/pi.pdf
   Google Scholar
• Pergola PE, Spiegel DM, Warren S, et al. Patiromer lowers serum potassium when taken without food: comparison to dosing with food from an open-label, randomized, parallel group hyperkalemia study. Am J Nephrol. 2017;46:323–332.
   PubMed Web of Science ®Google Scholar
• Montaperto AG, Gandhi MA, Gashlin LZ, et al. Patiromer: a clinical review. Curr Med Res Opin. 2016;32:155–164.
   PubMed Web of Science ®Google Scholar
• Bushinsky DA, Williams GH, Pitt B, et al. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney Int. 2015;88:1427–1433.
   PubMed Web of Science ®Google Scholar
• Bushinsky DA, Spiegel DM, Gross C, et al. Effect of patiromer on urinary ion excretion in healthy adults. Clin J Am Soc Nephrol. 2016;11:1769–1776.
   PubMed Web of Science ®Google Scholar
• Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011;32:820–828.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA. 2015;314:151–161.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Rossignol P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2019;394:1540–1550.
   PubMed Web of Science ®Google Scholar
• Wiederkehr MR, Mehta AN, Emmett M. Case report: patiromer-induced hypercalcemia. Clin Nephrol Case Stud. 2019;7:51–53.
   PubMedGoogle Scholar
• Rafique Z, Liu M, Staggers KA, et al. Patiromer for treatment of hyperkalemia in the emergency department: a pilot study. Acad Emerg Med. 2020;27:54–60.
   PubMed Web of Science ®Google Scholar
• Rattanavich R, Malone AF, Alhamad T. Safety and efficacy of patiromer use with tacrolimus in kidney transplant recipients. Transplant Int. 2019;32:110–111.
   PubMed Web of Science ®Google Scholar
• Lim MA, Sawinski D, Trofe-Clark J. Safety, effectiveness, and tolerability of patiromer in kidney transplant recipients. Transplantation. 2019;103:e281–e282.
   PubMed Web of Science ®Google Scholar
• Kovesdy CP, Rowan CG, Conrod A, et al. Real-world evaluation of patiromer for the treatment of hyperkalemia in hemodialysis patients. Kidney Int Rep. 2019;4:301–309.
   PubMed Web of Science ®Google Scholar
• Desai NR, Rowan CG, Alvarez PJ, et al. Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization. PLoS One. 2020;15:e0226844.
   PubMed Web of Science ®Google Scholar
• Clase CM, Carrero JJ, Ellison DH, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 2020;97:42–61.
   PubMed Web of Science ®Google Scholar
• Palmer BF, Colbert G, Clegg DJ. Potassium homeostasis, chronic kidney disease, and the plant-enriched diets. Kidney. 2020;360(1):65–71.
   Google Scholar
• Bushinsky DA, Rossignol P, Spiegel DM, et al. Patiromer decreases serum potassium and phosphate levels in patients on hemodialysis. Am J Nephrol. 2016;44(5):404–410.
   PubMed Web of Science ®Google Scholar